R- and S-salsolinol are not increased in cerebrospinal fluid of Parkinsonian patients

Journal of the Neurological Sciences

Volumn 164, Issue 2, 1999, Pages 158-162

  Müller, Thomas ^a   Sällström Baum, Siedy ^b   Häussermann, Peter ^a   Przuntek, Horst ^a   Rommelspacher, Hans ^b   Kuhn, Wilfried ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cerebrospinal fluid; Enantiomers; N methylation; Parkinson's disease; Salsolinol

Indexed keywords

DOPAMINE; SALSOLINOL; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENANTIOMER; FEMALE; HUMAN; MALE; METHYLATION; NEUROTOXICITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; PARKINSON DISEASE; REFERENCE VALUES; STEREOISOMERISM;

EID: 18744424010     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00058-1     Document Type: Article

References (34)

1. Antkiewicz-Michaluk L., Krygowska-Wajs A., Szczudlik A., Romanska I., Vetulani J. Increase in Salsolinol level in the cerebrospinal fluid of Parkinsonian Patients is related to dementia: Advantage of a new High-Performance Liquid Chromatography Methodology. Biol Psychiatry. 42:1997;514-518.
2. Collins M.A., Neafsey E.J., Matsubara K., Cobuzzi R., Albores R., Fields J., Rollema H. Indole-N-methylation of beta-carbolines: the brain's bioactivation route to toxins in Parkinson's disease ? Ann NY Acad Sci. 648:1992;263-265.
3. Collins M.A., Neafsey E.J., Matsubara K., Cobuzzi R., Rollema H. Indole-N-methylated beta-carbolinium ions as potential brain-bioactivated neurotoxins. Brain Res. 570:1992;154-160.
4. Deng Y., Maruyama W., Kawai M., Dostert P., Yamamura H., Takahashi T., Naoi M. Assay for the (R)- and (S)-enantiomers of salsolinols in biological samples and foods with ion-pair high-performance liquid chromatography using beta-cyclodextrin as a chiral mobile phase additive. J Chromatogr B Biomed Appl. 689:1997;313-320.
5. Dostert P., Strolin Benedetti M., Bellotti V., Allievi C., Dordain G. Biosynthesis of salsolinol, a tetrahydroisoquinoline alkaloid, in healthy subjects. J Neural Transm Gen Sect. 81:1990;215-223.
6. Dostert P., Strolin Benedetti M., Della Vedova F., Allievi C., La Croix R., Dordain G., Vernay D., Durif F. Dopamine-derived tetrahydroisoquinolines and Parkinson's disease. Adv Neurol. 60:1993;218-223.
7. Dostert P., Strolin Benedetti M., Dordain G., Vernay D. Enantiomeric composition of urinary salsolinol in Parkinsonian patients after Madopar. J Neural Transm PD Sect. 1:1989;269-278.
8. Dostert P., Strolin Benedetti M., Dordain G., Vernay D. Urinary elimination of salsolinol enantiomers in alcoholics. J Neural Transm Gen Sect. 85:1991;51-59.
9. Dostert P., Strolin Benedetti M., Dordain G. Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's diseases. J Neural Transm. 74:1988;61-74.
10. Faraj B.A., Camp V.M., Davis D.C., Lenton J.D., Kutner M. Elevation of plasma salsolinol sulfate in chronic alcoholics as compared to nonalcoholics. Alcohol Clin Exp Res. 13:1989;155-163.
11. Faraj B.A., Camp V.M., Kutner M. Interrelationship between activation of dopaminergic pathways and cerebrospinal fluid concentration of dopamine tetrahydroisoquinoline metabolite salsolinol in humans: preliminary findings. Alcohol Clin Exp Res. 15:1991;86-89.
12. Feest U., Kemper A., Nickel B., Rabe H., Koalick F. Comparison of salsolinol excretion in alcoholics and nonalcoholic controls. Alcohol. 9:1992;49-52.
13. Kikuchi K., Nagatsu Y., Makino Y., Mashino T., Ohta S., Hirobe M. Metabolism and penetration through blood-brain barrier of Parkinsonism-related compounds 1,2,3,4-Tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. Drug Metab Dispos. 19:1991;257-262.
14. Maruyama W., Abe T., Tohgi H., Dostert P., Naoi M. A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in Parkinsonian cerebrospinal fluid. Ann Neurol. 40:1996;119-122.
15. Maruyama W., Dostert P., Matsubara K., Naoi M. N-methyl(R)salsolinol produces hydroxyl radicals: involvement to neurotoxicity. Free Radic Biol Med. 19:1995;67-75.
16. Maruyama W., Dostert P., Naoi M. Dopamine-derived 1-methyl-6,7-dihydroxyisoquinolines as hydroxyl radical promoters and scavengers in the rat brain: in vivo and in vitro studies. J Neurochem. 64:1995;2635-2643.
17. Maruyama W., Narabayashi H., Dostert P., Naoi M. Stereospecific occurrence of a Parkinsonism-inducing catechol isoquinoline N-methyl(R)salsolinol, in the human intraventricular fluid. J Neural Transm. 103:1996;1069-1076.
18. Maruyama W., Sobue G., Matsubara K., Hashizume Y., Dostert P., Naoi M. A dopaminergic neurotoxin, 1(R), 2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl(R)salsolinol, and its oxidation product, 1,2(N)-dimethyl-6,7-dihydroxyisoquinolinium ion, accumulate in the nigrostriatal system of the human brain. Neurosci Lett. 223:1997;61-64.
19. Maruyama W., Takahashi T., Minami M., Takahashi A., Dostert P., Nagatsu T., Naoi M. Cytotoxicity of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines. Adv Neurol. 60:1993;224-230.
20. Moser A., Kömpf D. Presence of methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines, derivatives of the neurotoxin isoquinoline, in Parkinsonian lumbar CSF. Life Sci. 50:1992;1885-1891.
21. Moser A., Scholz J., Nobbe F., Vieregge P., Bohme V., Bamberg H. Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease. J Neurol Sci. 131:1995;183-189.
22. Moser A., Siebecker F., Vieregge P., Jaskowski P., Kömpf D. Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. J Neural Transm. 103:1996;421-432.
23. Naoi M., Dostert P., Yoshida M., Nagatsu T. N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins. Adv Neurol. 60:1993;212-217.
24. Naoi M., Maruyama W., Dostert P., Hashizume Y., Nakahara D., Takahashi T., Ota M. Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline N-methyl-(R)-salsolinol, induced Parkinsonism in rat: biochemical, pathological and behavioral studies. Brain Res. 709:(R):1996;285-295.
25. Naoi M., Maruyama W., Dostert P., Hashizume Y. N-methyl-(R)salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease. J Neural Transm Suppl. 50:1997;89-105.
26. Naoi M., Maruyama W., Dostert P., Kohda K., Kaiya T. A novel enzyme enantio-selectively synthesises (R)salsolinol, a precursor of a dopaminergic neurotoxin N-methyl(R)salsolinol. Neurosci Lett. 212:1996;183-186.
27. +-like neurotoxin, 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion in the substantia nigra of human brain. Neurosci Lett. 235:1997;81-84.
28. Naoi M., Maruyama W., Nakao N., Ibi T., Sahashi K., Strolin Benedetti M. (R)Salsolinol N-methyltransferase activity increases in Parkinsonian lymphocytes. Ann Neurol. 43:1998;212-216.
29. Naoi M., Maruyama W., Niwa T., Nagatsu T. Novel toxins and Parkinson's disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin. J Neural Transm Suppl. 41:1994;197-205.
30. Origitano T., Hannigan J., Collins M.A. Rat brain salsolinol and blood brain barrier. Brain Res. 224:1981;446-451.
31. Rommelspacher H., Sällström Baum S., Dufeu P., Schmidt L.G. Determination of (R)- and (S)-salsolinol sulfate and dopamine sulfate levels in plasma of nonalcoholics and alcoholics. Alcohol. 12:1995;309-315.
32. Sällström Baum S., Rommelspacher H. Determination of total dopamine, R- and S-salsolinol in human plasma by cyclodextrin bonded-phase liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl. 660:1994;235-241.
33. Strolin Benedetti M., Dostert P., Carminati P. Influence of food intake on the enantiomeric composition of urinary salsolinol in man. J Neural Transm Gen Sect. 78:1989;43-51.
34. Williams A.C., Pall H.S., Steventon G.B., Green S., Buttrum S., Molloy H., Waring R.H. N-methylation of pyridines and Parkinson's disease. Adv Neurol. 60:1993;194-196.